Intranasal Drug Delivery Devices Market Poised to Witness High Growth Owing to Increased Adoption of Self-Administered Drugs
![]() |
Intranasal Drug Delivery Devices market Demand |
The intranasal drug delivery devices market offers a
non-invasive alternate route of drug delivery to bypass first-pass metabolism.
Intranasal drug delivery provides direct entry of drugs into systemic circulation,
facilitates quick absorption, and enables self-administration of drugs.
Intranasal drug delivery devices deliver medications to treat various
conditions including allergies, migraines, nausea, pain, and infections. The
market has benefited from advantages such as rapid onset of action, ease of
administration even by untrained personnel, and delivery of large molecules
that are difficult to absorb through other routes.
The Global Intranasal Drug Delivery
Devices Market is estimated to be valued at US$ 3.27 Bn in 2024 and is expected
to exhibit a CAGR of 13% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Intranasal Drug Delivery Devices are
GlaxoSmithKline PLC, AstraZeneca PLC, Pfizer, Inc., OptiNose, Inc., 3M Company,
Becton, Dickinson and Company, Promius Pharma, LLC, Cadila Pharmaceuticals
Ltd., B.F. Ascher & Company, Inc., PendoPharm, Inc., Douglas
Pharmaceuticals Ltd., ENT Technologies Pty. Ltd., NAVEH Pharma Ltd., Novartis
AG, Neurelis, Inc., Aptargroup, Inc. These players are focusing on new product
launches and approvals to gain a competitive edge in the market.
The key opportunities in the Intranasal
Drug Delivery Devices market Demand include a large patient pool
suffering from conditions requiring self-administration of drugs and
technological innovations to improve delivery and enhance patient compliance.
Global expansion remains a key strategy for leading players. The market is
expected to observe high demand in Asia Pacific and Latin America due to
growing healthcare infrastructure and increasing awareness.
Market Drivers
The increased adoption of self-administered drugs is anticipated to drive the
demand for intranasal drug delivery devices market. Intranasal drugs allow for
self-administration by patients, eliminating the need for trained healthcare
professionals. This provides independence to patients and flexibility in
emergency situations.
Market Restraints
Nasal membrane irritation is a major concern associated with intranasal drug
delivery. Frequent and long-term use of nasal sprays can cause thinning,
drying, inflammation, and discoloration of nasal tissues which reduces
effectiveness over time. This limits long-term usage of intranasal sprays.
Segment
Analysis
The intranasal drug delivery devices market can be segmented based on dosage
form, container type, application, end-users and distribution channels. Among
dosage forms, the sprays segment dominate the market and is expected to
continue its dominance over the forecast period. This is because sprays allow
for needle-free delivery of drugs, provide for convenient self-administration
and afford precise control and targeting of drug delivery.
Based on container type, the pressurized canisters segment lead the market
owing to their popularity in over-the-counter products as well as their ability
to target the upper posterior region of the nasal cavity for effective systemic
delivery. Multidose devices are also expected to grow at a faster rate due to
rising adoption of portable reusable devices.
The allergy treatment segment accounts for the highest share in the intranasal
drug delivery devices market by application. This is attributed to growing
allergy rates worldwide coupled with greater uptake of intranasal
administration instead of oral formulations to avoid liver metabolism and
gastrointestinal degradation.
Global Analysis
Regionally, North America holds the largest share of the Intranasal
Drug Delivery Devices Market Regional Analysis and is estimated to
continue dominating over the forecast period. This is driven by rising
prevalence of allergic conditions, growing preference for self-administration
of medications, and advancements in device development by major players in the
region. Europe holds the second largest share and is expected to experience
notable growth due to increasing research activities evaluating intranasal
delivery potential for conditions like Parkinson’s disease. The Asia Pacific
region is likely to grow at the fastest pace owing to improving access to
healthcare and rising patient population seeking non-invasive treatment
options. Within Asia Pacific, China and India are projected to emerge as high
potential markets.
Get More
Insights On- Intranasal
Drug Delivery Devices Market
About
Author:
Priya Pandey is a dynamic and passionate editor with over
three years of expertise in content editing and proofreading. Holding a
bachelor's degree in biotechnology, Priya has a knack for making the content
engaging. Her diverse portfolio includes editing documents across different industries, including food
and beverages, information and technology, healthcare, chemical and materials,
etc. Priya's meticulous attention to detail and commitment to excellence
make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
Comments
Post a Comment